Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBP) Current Deferred Revenue (2017 - 2025)

Historic Current Deferred Revenue for Regen BioPharma (RGBP) over the last 6 years, with Q4 2025 value amounting to $1.3 million.

  • Regen BioPharma's Current Deferred Revenue fell 882.85% to $1.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.3 million, marking a year-over-year decrease of 882.85%. This contributed to the annual value of $1.3 million for FY2025, which is 863.79% down from last year.
  • According to the latest figures from Q4 2025, Regen BioPharma's Current Deferred Revenue is $1.3 million, which was down 882.85% from $1.3 million recorded in Q3 2025.
  • Regen BioPharma's 5-year Current Deferred Revenue high stood at $1.9 million for Q2 2021, and its period low was $1.3 million during Q4 2025.
  • In the last 4 years, Regen BioPharma's Current Deferred Revenue had a median value of $1.4 million in 2024 and averaged $1.5 million.
  • Per our database at Business Quant, Regen BioPharma's Current Deferred Revenue plummeted by 795.11% in 2024 and then tumbled by 882.85% in 2025.
  • Over the past 4 years, Regen BioPharma's Current Deferred Revenue (Quarter) stood at $1.9 million in 2021, then decreased by 15.14% to $1.6 million in 2023, then fell by 9.94% to $1.4 million in 2024, then fell by 8.83% to $1.3 million in 2025.
  • Its Current Deferred Revenue stands at $1.3 million for Q4 2025, versus $1.3 million for Q3 2025 and $1.4 million for Q2 2025.